Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/11/2025 | $6.00 | Sell | Goldman |
| 12/2/2024 | Outperform | BMO Capital Markets | |
| 9/3/2024 | $40.00 | Buy | Jefferies |
| 1/31/2024 | $67.00 | Outperform | BMO Capital Markets |
| 5/8/2023 | $20.00 | Overweight | Morgan Stanley |
| 12/9/2022 | $18.00 | Equal-Weight | Morgan Stanley |
| 3/31/2022 | $33.00 | Buy | Chardan Capital Markets |
Updated Phase 1 Data Presented at EHA 2025 Annual Meeting Reinforce Safety Profile, Efficacy Data and Dosing Convenience of Divesiran Company Also Announces SANRECO Phase 2 Study Has Exceeded 50% Enrollment - On-track for Full Enrollment by Year-End 2025 Silence Therapeutics plc ("Silence" or the "Company") (NASDAQ:SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today presented additional data showcasing the SANRECO Phase 1 study of divesiran in patients with polycythemia vera (PV) at the European Hematology Association (EHA) 2025 Annual Meeting in Milan, Italy. "The latest data presented at EHA today continue to demonstrate divesiran's
Company further extends cash guidance into 2028 Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial results for the first quarter ended March 31, 2025, and reviewed recent business highlights. "Silence delivered another strong quarter focused on clinical and operational execution," said Craig Tooman, President and Chief Executive Officer at Silence. "We remain focused on advancing enrollment into the SANRECO Phase 2 study of divesiran, a first-in-class siRNA program in PV, and continue to be on-track to complete enrollment by the end of this year. We are a
Mr. McInerney brings over 30 years of industry experience spanning senior executive, finance and capital advisory roles in the pharmaceutical and biotechnology sectors Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced the appointment of Tim McInerney to the Company's Board of Directors, effective immediately. Mr. McInerney will stand for re-appointment to the Silence Board at the Annual General Meeting ("AGM") in June 2025. "We are thrilled to welcome Tim to the Silence Board," said Iain Ross, Chairman of the Silence Board. "Tim is a seasoned executive and board memb
DEF 14A - Silence Therapeutics plc (0001479615) (Filer)
SCHEDULE 13G/A - Silence Therapeutics plc (0001479615) (Subject)
10-Q - Silence Therapeutics plc (0001479615) (Filer)
Goldman initiated coverage of Silence Therapeutics with a rating of Sell and set a new price target of $6.00
BMO Capital Markets reiterated coverage of Silence Therapeutics with a rating of Outperform
Jefferies initiated coverage of Silence Therapeutics with a rating of Buy and set a new price target of $40.00
4 - Silence Therapeutics plc (0001479615) (Issuer)
4 - Silence Therapeutics plc (0001479615) (Issuer)
4 - Silence Therapeutics plc (0001479615) (Issuer)